Skip to content
Home
Medical Need
Our Science
Our Program
Our Team
News
Home
Medical Need
Our Science
Our Program
Our Team
News
CONTACT US
Vaderis Expanded Access Policy >
Home
Medical Need
Our Science
Our Team
Our Program
News
Contact Us
Expanded Access Policy
Home
Medical Need
Our Science
Our Team
Our Program
News
Contact Us
Expanded Access Policy
News
Vaderis News |
08/11/2026
Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
READ MORE
Vaderis News |
04/16/2026
Vaderis Announces Participation in Mass General Brigham Life Changing Research Town Hall
READ MORE
Vaderis News |
12/02/2025
Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results
READ MORE
Vaderis News |
11/17/2024
Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia
READ MORE
Vaderis News |
11/05/2024
Vaderis Announces Acceptance of Abstract on VAD044 Proof-of-Concept Clinical Trial
READ MORE
Vaderis News |
08/27/2024
Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT
READ MORE
